Trial Profile

To Evaluate the Safety of RC88 for Injection in Patients with Advanced Malignant Solid Tumors,Multicenter, Open, Multi-cohort Extension of Efficacy and Pharmacokinetic Characteristics Phase I /IIa Clinical Study

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RC 88 (Primary)
Indications Adenocarcinoma; Gastric cancer; Lung cancer; Malignant-mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors RemeGen

27 Jan 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.
27 Jan 2025 Planned primary completion date changed from 30 Sep 2024 to 30 Nov 2025.
04 Jun 2024 The efficacy results from the dose expansion part (phase 2) of the study (n=164) presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com